Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Introduces Corporate Emissions Calculator as Pressure to Quantify Carbon Exposure Accelerates29.4.2026 15:10:00 CEST | Press release
Digital tool enables companies to rapidly assess emissions and take immediate action while preparing for compliance and carbon market participation. CALGARY, AB / ACCESS Newswire / April 29, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today highlighted its Corporate Emissions Calculator, a digital tool designed to help organizations quickly quantify emissions across key operational areas and move from measurement to action. As regulatory frameworks evolve and expectations around emissions disclosure increase, organizations across sectors including energy, manufacturing, aviation, and logistics are facing accelerating pressure to understand and manage their carbon exposure. Many existing solutions remain complex, time-intensive, and reliant on external consultants, creating delays at a time when companies are being pushed to act faster and with greater preci
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses28.4.2026 16:00:00 CEST | Press release
TruMerit 2025 Nurse Migration Report reveals workforce inequities widening across regions. PHILADELPHIA, PA / ACCESS Newswire / April 28, 2026 / TruMerit™ (formerly CGFNS International) today released its 2025 Nurse Migration Report, revealing significant shifts in global nurse migration patterns and widening inequities in nursing workforce distribution across regions with vastly different healthcare needs. The report, which analyzes World Health Organization data and TruMerit's proprietary VisaScreen® application records, shows that international nurse migration flows are increasingly concentrated in regions with stronger healthcare infrastructure, while areas facing severe nursing shortages continue to lose ground in their ability to employ internationally educated nurses. Europe and Southeast Asia see sharp increases in international nurse employment. According to TruMerit's analysis of WHO nursing workforce data, Europe now employs internationally educated nurses at a rate represen
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture28.4.2026 15:00:00 CEST | Press release
Tenstorrent GalaxyTM Blackhole delivers general-purpose AI with native scale-out for winning performance in AI video generation and LLMs - prefill and decode. SANTA CLARA, CA / ACCESS Newswire / April 28, 2026 / Tenstorrent, the AI compute company led by CEO, Jim Keller, announces today general availability of Tenstorrent Galaxy Blackhole deployed at scale, delivering industry-leading general-purpose AI performance. Other solutions require bolting together separate accelerators across fragmented infrastructure. Tenstorrent's Networked AI delivers them natively - compute, memory, and networking unified into a single system optimized for real-world AI workloads. Leading Industry Performance, Affordable Prices General-purpose means leading performance on every workload defining modern AI, not specializing in one. Tenstorrent Galaxy tops video generation, large-context LLM inference in both prefill and decode, and the full range of model architectures shipping today. See it for yourself on
Kontent.ai Appoints Mark Greenaway as CEO to Drive the Next Phase of AI in Enterprise Content27.4.2026 08:00:00 CEST | Press release
BRNO, CZ / ACCESS Newswire / April 27, 2026 / Kontent.ai has appointed Mark Greenaway as Chief Executive Officer, as the company looks to scale its Agentic CMS and transform content operations for customers. Greenaway brings a track record of scaling businesses and leading high performing global teams with a focus on enterprise environments where content is both a marketing asset and a critical driver of growth, compliance, and customer experience. With this appointment, Kontent.ai founder Petr Palas returns to his position on the board at Kontent.ai and will continue to support the business he launched in 2022 as a successful spin out of Kentico. Kontent.ai recently launched their next generation of "Agentic CMS" with the launch of Expert Agents. These Agents are embedded directly into workflows to continuously handle operational tasks such as governance, search and generation engine (LLM) optimization, translation, and lifecycle management, work that typically requires significant ma
HrFlow.ai Secures 7 Million Dollars (Pre-Series A) to Become the Global Standard for Artificial Intelligence (AI) Applied to HR Data24.4.2026 01:40:00 CEST | Press release
PARIS, FR / ACCESS Newswire / April 23, 2026 / 1. Fundraising and Objectives HrFlow.ai, a pioneer in Artificial Intelligence applied to Human Resources data, announces its second fundraising round of $7M (pre-Series A) today. This financing brings the company's total capital raised to $10 million. This new capital injection is designed to accelerate the company's core mission: building the Data & AI infrastructure of the labor market. The round is led by 115K, La Banque Postale's venture capital fund, and EmergingTech Ventures (EmTech), alongside the company's existing investors including Xavier Niel (Free, Kima, Station F), Jean-Baptiste Rudelle (Criteo), Romain Niccoli (Pigment, Criteo), Franck Le Ouay (LIFEN, Criteo), Flavien Kulawik (KLB), Allen Penn (Uber), Dominique Vidal (Index Ventures), Thibaud Elzière (Hexa, Fotolia). Building on rigorous execution and proven capital efficiency since its first funding round of $2.3M in 2018, HrFlow.ai now generates a margin of approximately 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom